Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24311874 | 1.00 | LRRK2 (0.31) | LRRK2MAP3K12 | |
| SCHEMBL25653333 | 0.82 | KDM2B (0.39) | — | |
| SCHEMBL24904229 | 0.78 | — | — | |
| SCHEMBL24827995 | 0.77 | — | — | |
| SCHEMBL24827994 | 0.77 | — | — | |
| SCHEMBL17660700 | 0.77 | LRRK2 (0.32) | LRRK2MAP3K12 | |
| SCHEMBL21204597 | 0.77 | LRRK2 (0.32) | LRRK2 | |
| SCHEMBL21610993 | 0.77 | LRRK2 (0.32) | LRRK2 | |
| SCHEMBL22182247 | 0.76 | LRRK2 (0.35) | LRRK2MAP3K12 | |
| SCHEMBL29316697 | 0.76 | KDM2B (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | LRRK2 1/4885MAP3K12 190/4885 |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | EGFR, ERBB2, ERBB3 | LRRK2 224/4885MAP3K12 177/4885 |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | LRRK2 224/4885MAP3K12 177/4885 |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | LRRK2 1/4885MAP3K12 1662/4885 |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | PHKG1, MAP4K5, HIPK1 | LRRK2 2602/4885MAP3K12 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.